Vertex Pharmaceuticals Incorporated announced revenue results for the fourth quarter and full year of 2015. The company announced that fourth quarter 2015 net product revenues of approximately $180 million for kalydeco and $220 million for orkambi; total 2015 net CF product revenues of approximately $980 million, an increase of more than 110% versus 2014.

For the year, the company net product Revenue was $350 million for orkambi and $630 million for kalydeco.

The company provided revenuer guidance for the year 2016. For the year, the company provided guidance for KALYDECO net product revenues of $670 million to $690 million and for non-GAAP operating expenses, excluding costs of revenues, of $1.18 to $1.23 billion.